Douglas Merkel to Breast Neoplasms
This is a "connection" page, showing publications Douglas Merkel has written about Breast Neoplasms.
Connection Strength
0.391
-
Primary factor in declining breast cancer mortality rates: early detection or adjuvant therapy? Cancer Pract. 2002 Jan-Feb; 10(1):45-7.
Score: 0.079
-
Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015. Breast Cancer Res Treat. 2020 Jun; 181(3):623-633.
Score: 0.071
-
Achieving local control for inflammatory carcinoma of the breast. Surg Gynecol Obstet. 1992 Aug; 175(2):141-4.
Score: 0.041
-
Incidence and management of arthralgias in breast cancer patients treated with aromatase inhibitors in an outpatient oncology clinic. J Oncol Pharm Pract. 2012 Dec; 18(4):387-93.
Score: 0.040
-
Priority symptoms in advanced breast cancer: development and initial validation of the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy-Breast Cancer Symptom Index (NFBSI-16). Value Health. 2012 Jan; 15(1):183-90.
Score: 0.039
-
The importance of DNA flow cytometry in node-negative breast cancer. Arch Surg. 1990 Jul; 125(7):886-9.
Score: 0.036
-
Prognostic factors in breast cancer. Hematol Oncol Clin North Am. 1989 Dec; 3(4):641-52.
Score: 0.034
-
Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study. J Natl Cancer Inst. 2006 Dec 20; 98(24):1767-76.
Score: 0.028
-
Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial. J Clin Oncol. 2004 Mar 15; 22(6):1071-7.
Score: 0.023